Kenvue (KVUE)
Consumer Staples · consumer staples / household & personal care products · NYSE
Kenvue is a pure-play consumer health giant managing a portfolio of iconic, science-backed brands across personal care, skin health, and essential household wellness products.
What Kenvue does
Kenvue is a global consumer health company that manufactures and markets a diverse portfolio of household-name brands in personal health, skin health, and beauty. The company's products are sold across various retail channels, including e-commerce, drug stores, mass merchandisers, and grocery chains. Formerly the consumer health division of Johnson & Johnson, Kenvue focuses on delivering science-backed care for everyday health needs.
Themes: consumer health, personal care and beauty, over-the-counter medicine, skincare, household essentials, brand management
Fundamentals
- Price$19.43 as of 2026-08-24 close
- Market cap$37.3B as of 2026-08-24
- 1-year return-10.1% 2025-08-22 close $21.61 → 2026-08-24 close $19.43
- P/E22.53 as of 2026-08-24
- Net margin+10.8% as of 2026-08-24
- Gross margin+58.6% as of 2026-08-24
- ROE+15.6% as of 2026-08-24
- Debt / equity0.80 as of 2026-08-24
- Revenue growth (YoY)+1.8% as of 2026-08-24
- Revenue CAGR (3y)+0.2% SEC XBRL
- Beta0.18 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +4.3%; at least 3 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How KVUE compares in its sector
- price-to-earnings ratiomiddle range 94 covered Consumer Staples peers, as of 2026-08-24
- net profit margintop 25% 116 covered Consumer Staples peers, as of 2026-08-24
- operating margintop 25% 116 covered Consumer Staples peers, as of 2026-08-24
- gross margintop 25% 116 covered Consumer Staples peers, as of 2026-08-24
- return on equitymiddle range 116 covered Consumer Staples peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 109 covered Consumer Staples peers
- indicated dividend yieldtop 25% 77 covered Consumer Staples peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 25% 110 covered Consumer Staples peers, as of FY2025
Position among covered Consumer Staples companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
KVUE is not currently in any published Top 10 list. Its scores are below.
Long-term score
45.0 #1097 of 1,605 scored · #35 of 69 in Consumer Staples
Profitability 60th (operating margin 17.1%, return on equity 15.6%) and capital return 51st (consecutive years of dividend increases 3 years); weakest is growth (21st, 3-year revenue CAGR 0.2%, revenue growth year over year 1.8%).
Short-term score
48.3 #761 of 1,698 scored · #31 of 69 in Consumer Staples
Trend 55th: the price is 2% above the average price paid over the period covered, so the typical buyer over that stretch is showing a gain; volume and participation 55th: it gapped 3.2% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is setup 34th: no fresh 20-day breakout up or down.
Scores as of 24 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
Dividend coverage (FY2025)
Exceeded at least one reported measure. In FY2025, KVUE's dividend exceeded at least one reported measure of what it earned or generated (earnings payout 108%, free-cash-flow payout 92%). A payout above 100% in one year is not necessarily unsustainable, but it is not fully covered by that measure.
- Earnings payout108% dividends / net income
- Free-cash-flow payout92% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Kenvue looks technically
Kenvue (KVUE) is trading 9.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 49 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 9.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +9.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $19.05 | $19.05 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $17.78 | $17.78 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 12 calendar days ago — the swings before that are what the structure reading is measured on | 12 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 18.65. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 49 trading days ago — a "golden cross", a bullish long-term signal | 49 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 12.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 56, neither overbought (above 70) nor oversold (below 30) | 56.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($18.65 to $19.70) — its "stochastic" reading is 74 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 74.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $21.84 | $21.84 |
|---|---|---|
| From the 52-week high | it is 11.1% below its 52-week high (its highest price of the past year) | -11.1% |
| Above the 52-week low | it is 38.6% above its 52-week low (its lowest price of the past year) | +38.6% |
| Below the 52-week high | it is 11.1% below its highest point of the past year | 11.1% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day high about 37 trading days ago | 37 sessions |
| All-time high | its highest closing price on record is $27.80 (set on 2023-05-15) | $27.80 |
| Given back of the 52-week move | over the past year its closes ranged ($14.11 to $21.63), and it has recovered well over two thirds of its fall from last year’s high — 71% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $18.76 to $19.00. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 70.7% |
| From the all-time high | it is 30.1% below its all-time high | -30.1% |
| Nearest price level | it is trading 1.4% above a support level at $19.15 — a price it turned at three times since 2026-02-12, most recently on 2026-08-14. Since 2024-08-26 it has 6 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.4% |
| All-time low | its lowest closing price on record is $14.02 (set on 2025-10-30) | $14.02 |
| Above the all-time low | it is 38.6% above its all-time low | +38.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 37th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4192 between its high and its low — about 2.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4192 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $18.65 and $19.79 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $18.65 – $19.22 – $19.79 |
| Typical daily range (% of price) | its price moves about 2.2% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.2% |
| Stretch from the 200-day average | it is trading 3.9 daily ranges above its 200-day average price (9.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.77× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-24 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.2% |
|---|---|---|
| Open gap | it gapped 3.2% above the previous close 50 sessions ago and has not traded back through the level it left behind at 17.55 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.2% |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +2.64% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.5 percentage points (the stock gained 0.8% while the market gained 3.3%) | -2.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 8.4 percentage points (the stock gained 10.8% while the market gained 2.4%) | +8.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 8.9 percentage points (the stock gained 2.2% while the market gained 11.1%) | -8.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 28.4 percentage points (the stock lost 10.1% while the market gained 18.3%) | -28.4% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 1.8% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.1% of the share price. | +1.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $18.03 — a volume-weighted average of daily closes over 156 sessions, not a true tick-by-tick VWAP. | +7.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $19.06 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +1.9% |
Price levels it has turned at before
KVUE last closed at $19.43 on 2026-08-24. Since 2024-08-26 it has turned at 6 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $19.15 | Support | 1.4% below the last close | turned there three times · 2026-02-12 to 2026-08-14 |
| $19.98 | Resistance | 2.8% above the last close | turned there three times · 2025-02-06 to 2026-07-28 |
| $18.67 | Support | 3.9% below the last close | turned there four times · 2026-07-15 to 2026-08-12 |
| $20.62 | Resistance | 6.1% above the last close | turned there four times · 2025-01-10 to 2025-08-14 |
| $17.81 | Support | 8.4% below the last close | turned there 9 times · 2025-12-01 to 2026-06-22 |
| $21.16 | Resistance | 8.9% above the last close | turned there three times · 2024-10-10 to 2025-06-09 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $18.65.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · trendless / choppy (low ADX) · lagging the market · Trading above the Ichimoku cloud · Near a support level (sitting on a price it has bounced off before) | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.79 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$19.50 range $18.00 – $23.00; median $19.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for KVUE
- Consensus EPS estimate$0.2945 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Product reliability, safety, and efficacy concerns leading to regulatory action or litigation","Intense competition from private-label brands and generic products","Operational risks related to global supply chain disruptions and manufacturing delays"]
What changed in the latest 10-Q
AI-assisted comparison of KVUE's 10-Q filed 2026-05-07 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report for fiscal twelve months ended December 28, 2025, filed February 20, 2026 (vs. older filing's December 29, 2024, filed February 24, 2025)
- Newer filing states Net sales of $15.1 billion in fiscal year 2025 (vs. older filing's $15.5 billion in fiscal year 2024)
- Newer filing includes new section 'Pending Transaction with K-C' describing merger agreement approved November 2, 2025, with share and cash consideration terms, expected closing in second half of 2026, shareholder approval January 29, 2026, and Hart-Scott-Rodino waiting period expiration February 4, 2026
- Newer filing includes language about incurring costs for 'Pending Transaction and other related costs' including advisory, legal, and professional service fees
- Newer filing includes section 'Recent Developments' with subsection 'Conflict in the Middle East' (text appears truncated)
- Newer filing reorganizes Separation from J&J section to appear after Pending Transaction section rather than before
- Removed:
- Older filing's introductory sentence referencing 'Unless otherwise defined herein, capitalized terms related to the proposed Transaction used in this Management's Discussion and Analysis' is removed in newer filing
- Older filing's detailed historical narrative of Separation process (November 2021 announcement, February 2022 incorporation, April 2023 asset transfer, May 2023 IPO, July 2023 Exchange Offer announcement, August 2023 completion, May 2024 Debt-for-Equity Exchange) is consolidated and shortened in newer filing
- Older filing's separate 'Relationship with J&J' section header and content is removed (merged into reorganized 'Separation from J&J' section in newer filing)
- Older filing's reference to 'Kenvue Global and North America Headquarters' section beginning on April 20, 2023 lease is removed
- Older filing mentions 'proposed Transaction' multiple times; newer filing replaces with 'Pending Transaction'
- Reworded:
- Older filing states 'with —in their daily rituals and the moments that matter most' while newer filing states 'in their daily rituals and the moments that matter most' (dash removed)
- Older filing states R&D organization has 'engagement with healthcare professionals' while newer filing states 'active engagement with healthcare professionals'
- Self Care segment brand order differs: older lists 'Tylenol ® , Motrin ® , Nicorette ® , Benadryl ® , Zyrtec ® , Zarbee's ® , ORSL ® , Rhinocort ® , and Calpol ®' while newer lists 'Benadryl ® , Calpol ® , Motrin ® , Nicorette ® , Rhinocort ® , Tylenol ® , Zarbee's ® , and Zyrtec ®' (ORSL ® removed from newer)
- Skin Health and Beauty segment brand order differs between filings
- Essential Health segment brand order differs between filings
- Older filing uses 'proposed Transaction' terminology while newer filing uses 'Pending Transaction' throughout
- Newer filing describes Separation more concisely as completed in August 2023 rather than older filing's detailed multi-step narrative
- Notes:
- Newer filing text appears truncated at 'Conflict in the Middle East' section beginning
- Older filing text also appears truncated at 'Kenvue Global and North America Headquarters' section
- Comparison limited to provided text segments; full sections may contain additional changes not visible in truncated versions
Risk Factors
- Added:
- Reference to 'Pending Transaction' (defined in Note 1) instead of 'proposed Transaction' (defined in Note 16) in the forward-looking statements introduction (filed 2026-05-07)
- New bullet point: 'The development, deployment, use, and regulation of artificial intelligence in our internal processes, manufacturing operations, products and services, as well as our business more broadly;' appears in newer filing (filed 2026-05-07)
- Statement that 'The forward-looking statements in this report, other than the statements regarding the Pending Transaction with Kimberly-Clark, do not assume the consummation of the Pending Transaction unless specifically stated otherwise' (filed 2026-05-07)
- Removed:
- Reference to 'our proposed Transaction' in the forward-looking statements introduction (filed 2025-11-03)
- Reference to 'our strategic review process' in the restructuring initiative risk factor (filed 2025-11-03)
- Reference to '2024 Multi-Year Restructuring Initiative' - replaced with '2026 Restructuring Initiative' (filed 2025-11-03)
- Phrase 'the emergence of e-commerce' - simplified to 'e-commerce' (filed 2025-11-03)
- Phrase 'environmental, social, and governance matters' - replaced with 'sustainability matters' (filed 2025-11-03)
- Detailed bullet point regarding talc litigation and J&J indemnification obligations specific to U.S. and Canada (filed 2025-11-03)
- Bullet point: 'Failure of our rebranding efforts in connection with the Separation to achieve market acceptance, and the impact of our continued use of legacy J&J branding' (filed 2025-11-03)
- Statement 'The forward-looking statements in this report, other than the statements regarding the proposed Transaction with Kimberly-Clark, do not assume the consummation of the proposed Transaction unless specifically stated otherwise' (filed 2025-11-03)
- Reworded:
- Changed 'proposed Transaction' to 'Pending Transaction' throughout document (filed 2026-05-07 vs 2025-11-03)
- Changed 'the emergence of e-commerce and other alternative retail channels' to 'e-commerce and other alternative retail channels' in retail landscape risk factor (filed 2026-05-07)
- Changed '2024 Multi-Year Restructuring Initiative' to '2026 Restructuring Initiative' (filed 2026-05-07)
- Removed 'our strategic review process,' from the list preceding the restructuring initiative reference (filed 2026-05-07)
- Changed 'environmental, social, and governance matters' to 'sustainability matters' in stakeholder expectations risk factor (filed 2026-05-07)
- Consolidated talc-related risks into single reference: 'legal proceedings relating to acetaminophen and talc or talc-containing products' rather than detailed separate talc bullet (filed 2026-05-07)
- Removed specific reference to 'Johnson's® Baby Powder' and U.S./Canada geographic limitation in talc litigation discussion (filed 2026-05-07)
- Removed reference to J&J indemnification obligations for 'Talc-Related Liabilities' (filed 2026-05-07)
- Text appears truncated in both versions at the end of the risk factors section
- Notes:
- The newer filing text appears truncated mid-sentence at the end ('consideration our s'), making complete assessment of final changes impossible
- The older filing text also appears truncated at the end ('Our ability to complete the proposed Transaction and uncer'), limiting comparison of closing risk factors
- Page number changes (from pages 60-65 in older to pages 43-45 in newer) reflect content reorganization but do not indicate substantive changes to risk factor content itself
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($66989) — 1 selling insider
- Last 180 days0 buys · 2 sells ($746679) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-10. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about KVUE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 15 matched disclosures for KVUE from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding KVUE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 417,176,775
- Reported value $7,192,127,583
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
KVUE had 63,304,672 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
KVUE had 3.30% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.41 days to cover at the same settlement.
- Reported short interest (shares) 63,304,672
- Short interest (% of shares outstanding) 3.30%
- Prior settlement (shares) 61,555,132
- Reported change 2.84%
- Days to cover (reported) 3.41
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Procter & Gamble (PG)
- Unilever
- Colgate-Palmolive (CL)
- Haleon
- Church & Dwight (CHD)
- Kimberly-Clark (KMB)
- L'Oréal (LRLCY)
- Reckitt Benckiser
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare KVUE vs…
Kenvue is found in…
Frequently asked questions
What does Kenvue (KVUE) do?
Kenvue is a global consumer health company that manufactures and markets a diverse portfolio of household-name brands in personal health, skin health, and beauty. The company's products are sold across various retail channels, including e-commerce, drug stores, mass merchandisers, and grocery chains. Formerly the consumer health division of Johnson & Johnson, Kenvue focuses on delivering science-backed care for everyday health needs.
What sector is Kenvue (KVUE) in?
Kenvue (KVUE) is classified in the Consumer Staples sector. Its industry is consumer staples / household & personal care products. It trades on NYSE.
Does KVUE pay a dividend?
Yes — Kenvue (KVUE) pays a dividend, with an indicated yield of about 4.32% and at least 3 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Kenvue's (KVUE) competitors?
Notable peers of Kenvue (KVUE) include Procter & Gamble, Unilever, Colgate-Palmolive, Haleon and Church & Dwight. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in KVUE?
Yes — we hold 15 matched STOCK Act disclosures for KVUE from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Kenvue (KVUE) overbought or oversold right now?
Kenvue (KVUE) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 56, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on KVUE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.